Tenax Therapeutics Inc

NASDAQ:TENX   3:59:51 PM EDT
1.62
-0.04 (-2.41%)
Products, Regulatory, Earnings Announcements

Tenax Therapeutics Announces Clearance Of The Investigational New Drug Application For Imatinib In Pulmonary Arterial Hypertension

Published: 10/06/2021 12:41 GMT
Tenax Therapeutics Inc (TENX) - Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (pah).
Tenax Therapeutics Inc - on Track to Initiate a Single Phase 3 in Pah in 2q 2022.
Tenax Therapeutics Inc - Anticipates Results From Pk Study in Q4 of 2021.
Tenax Therapeutics Inc - Expects to Initiate a Single Phase 3 Study in Q2 of 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.